Indegene Limited announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Q3). Key highlights include approval of financial results and limited review report, amendment to the Anti-Sexual Harassment Policy, allotment of shares under RSU 2020 Plan and re-constitution of Committees of the Board. The board meeting concluded at 6:07 P.M. IST on January 29, 2026.
Financial Performance Overview
Indegene Limited’s board of directors approved the unaudited standalone and consolidated financial results for Q3 (October-December) of FY26. The results, along with the auditors’ limited review report, show the company’s financial standing. The review report has an unmodified opinion.
Key Financial Figures (Consolidated)
The consolidated unaudited financial results reveal:
- Revenue: ₹25,071 million for the quarter.
- Profit after tax: ₹34 million for the nine months ended December 31, 2025.
Key Financial Figures (Standalone)
The standalone financial results reveal:
- Revenue: ₹8,524 million for the quarter.
- Profit after tax: ₹1.398 million for the nine months ended December 31, 2025.
Strategic Decisions and Updates
In addition to reviewing the financials, the board made the following decisions:
- Approved an amendment to the Anti-Sexual Harassment Policy.
- Approved the allotment of shares under the RSU 2020 Plan.
- Approved the re-constitution of Committees of the Board.
Acquisition and Expansion
Indegene continues to expand its capabilities through strategic acquisitions, including:
- BioPharm Parent Holding Inc: Acquired on October 1, 2025, for $104 million.
- Warn & Co Limited: Acquired on October 16, 2025, for GBP 3.91 million.
Furthermore, Indegene Ireland Limited signed a Share Purchase Agreement on November 10, 2025, to acquire CAKE Kommunikations Holding GmbH.
Source: BSE
